Adding external beam radiotherapy did not improve biochemical failure outcomes or prostate cancer specific mortality in ...
While they were both approved several years back to treat the same two types of prostate cancer, Astellas and Pfizer’s Xtandi ...
Prostate cancer is the most common solid organ cancer in American men and the second leading cause of cancer-related death ...
Johnson & Johnson reveals Erleada's 23% lower risk of death over Xtandi in a real-world study of prostate cancer patients, ...
Prostate cancer is the most commonly diagnosed cancer in males in 118 of 185 countries, but it's the leading cause of death ...
HOUSTON — September is Prostate Cancer Awareness Month. One in eight men will be diagnosed during their lifetime, and it's ...
New data show excellent quality-of-life outcomes and effective tumor control for both intensity-modulated radiation therapy ...
More than a third of men over the age of 40 have a prostate cancer screening with a PSA test. Still, experts agree it’s unclear if the benefits of the cancer screenings using PSA tests outweigh the ...
People with low- and intermediate-risk prostate cancer treated with either of two types of contemporary radiation ...